Source:http://linkedlifedata.com/resource/pubmed/id/11023459
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2000-12-1
|
| pubmed:abstractText |
The potential role of human immunodeficiency virus type 1 (HIV-1)-specific immune responses in controlling viral replication in vivo has stimulated interest in enhancing virus-specific immunity by vaccinating infected individuals with HIV-1 or its components. These studies were undertaken to define patient populations most likely to respond to vaccination, with the induction of novel HIV-1-specific cellular immune responses, and to compare the safety and immunogenicity of several candidate recombinant HIV-1 envelope vaccines and adjuvants. New lymphoproliferative responses (LPRs) developed in <30% of vaccine recipients. LPRs were elicited primarily in study participants with a CD4 cell count >350 cells/mm(3) and were usually strain restricted. Responders tended to be more likely than nonresponders to have an undetectable level of HIV-1 RNA at baseline (P=.067). Induction of new cellular immune responses by HIV-1 envelope vaccines is a function of the immunologic stage of disease and baseline plasma HIV-1 RNA level and exhibits considerable vaccine strain specificity.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0022-1899
|
| pubmed:author |
pubmed-author:BellDD,
pubmed-author:ChernoffDD,
pubmed-author:ChiuSS,
pubmed-author:CollierAA,
pubmed-author:CooneyEE,
pubmed-author:FriedlandGG,
pubmed-author:HaslettPP,
pubmed-author:HirschM SMS,
pubmed-author:JonesGG,
pubmed-author:KahnJJ,
pubmed-author:KetterNN,
pubmed-author:KunduSS,
pubmed-author:KuritzkesDD,
pubmed-author:McElrathM JMJ,
pubmed-author:MeriganT CTCJr,
pubmed-author:MitsuyasuRR,
pubmed-author:PlaegerSS,
pubmed-author:RosandichMM,
pubmed-author:SchooleyR TRT,
pubmed-author:SpinkGG,
pubmed-author:TwadellTT,
pubmed-author:UherovaPP,
pubmed-author:ValentineF AFA,
pubmed-author:WalkerB DBD,
pubmed-author:ZhangBB,
pubmed-author:deGruttolaVV
|
| pubmed:issnType |
Print
|
| pubmed:volume |
182
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1357-64
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:11023459-AIDS Vaccines,
pubmed-meshheading:11023459-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:11023459-Double-Blind Method,
pubmed-meshheading:11023459-Female,
pubmed-meshheading:11023459-Humans,
pubmed-meshheading:11023459-Lymphocyte Activation,
pubmed-meshheading:11023459-Male,
pubmed-meshheading:11023459-RNA, Viral,
pubmed-meshheading:11023459-Viral Envelope Proteins
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.
|
| pubmed:affiliation |
University of Colorado Health Sciences Center, Denver, CO, USA. Robert.Schooley@uchsc.edu
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|